Zain Ebrahim
Stock Analyst at J.P. Morgan
(1.22)
# 3,684
Out of 4,595 analysts
35
Total ratings
52.9%
Success rate
-2%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Sell | 1,700p | 1,932p | -11.99% | 25 | Jul 28, 2026 | |
| EPA: EAPI Euroapi S.A. | Maintained: Hold | €1.70 | €0.98 | +73.65% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Buy | 2,400p → 2,000p | 1,585p | +26.18% | 2 | Mar 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Hold | kr 1,650 → kr 2,050 | kr 1,833 | +11.82% | 2 | Dec 8, 2025 | |
| LON: OXB Oxford Biomedica plc | Maintained: Hold | 550p | 560p | -1.79% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 675.00 | CHF 562.20 | n/a | 1 | Jul 28, 2025 | |
| SWX: BANB Bachem Holding AG | Maintained: Buy | CHF 74.00 → CHF 85.00 | CHF 74.80 | n/a | 3 | Jul 25, 2025 |
GSK plc
Jul 28, 2026
Maintained: Sell
Price Target: 1,700p
Current: 1,932p
Upside: -11.99%
Euroapi S.A.
May 13, 2026
Maintained: Hold
Price Target: €1.70
Current: €0.98
Upside: +73.65%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Maintained: Buy
Price Target: 2,400p → 2,000p
Current: 1,585p
Upside: +26.18%
Genmab A/S
Dec 8, 2025
Maintained: Hold
Price Target: kr 1,650 → kr 2,050
Current: kr 1,833
Upside: +11.82%
Oxford Biomedica plc
Dec 8, 2025
Maintained: Hold
Price Target: 550p
Current: 560p
Upside: -1.79%
Lonza Group AG
Jul 28, 2025
Maintained: Buy
Price Target: CHF 675.00
Current: CHF 562.20
Upside: n/a
Bachem Holding AG
Jul 25, 2025
Maintained: Buy
Price Target: CHF 74.00 → CHF 85.00
Current: CHF 74.80
Upside: n/a